A Phase 1 Clinical Study Evaluating the Effects of Cenobamate on the QT Interval
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1077
Abstract: Cenobamate is an antiseizure medication for uncontrolled focal seizures. This thorough QT study assessed the effects of therapeutic and supratherapeutic cenobamate doses (maximum recommended dose, 400 mg/day) on correct QT interval (QTc) in healthy adults… read more here.
Keywords: 400 day; day; cenobamate days; cenobamate ... See more keywords